Effect of PPAR-γ agonist treatment on markers of endothelial dysfunction in patients with type 2 diabetes mellitus

Title:

Effect of PPAR-γ agonist treatment on markers of endothelial dysfunction in patients with type 2 diabetes mellitus

Creator:

Radka Doležalová, Michal Haluzík, Lenka Bošanská, Zdeňka Lacinová, Zdislava Kasalová, Tomáš Štulc, and Martin Haluzík

Identifier:

https://cdk.lib.cas.cz/client/handle/uuid:bd9c12c8-5875-4e28-bcd8-a53be8b252fe
uuid:bd9c12c8-5875-4e28-bcd8-a53be8b252fe
issn:0862-8408

Subject:

Fyziologie člověka a srovnávací fyziologie, fyziologie člověka, endoteliální dysfunkce, thiazolidindiony, human physiology, endothelial dysfunction, thiazolidindiones, cardiovascular risk, adipocyte-derived hormones, 14, and 612

Type:

article, články, model:article, and TEXT

Format:

print, bez média, and svazek

Description:

Thiazolidinediones are insulin-sensitizing drugs acting through peroxisome proliferator- activated receptor (PPAR)-γ. The aim of our study was to evaluate the effect of 5-month treatment with PPAR-γ agonist – rosiglitazone (4 mg/day), on the circulating markers of endothelial dysfunction and to evaluate the role of changes in endocrine function of adipose tissue in this process. Biochemical and metabolic parameters, circulating adiponectin, resistin, ICAM-1, VCAM-1, E-selectin, P-selectin, PAI-1, myeloperoxidase (MPO), and matrix metalloproteinase-9 (MMP-9) concentrations were assessed in 10 women with type 2 DM before and after rosiglitazone treatment and in a control group of healthy women. At baseline, diabetic group had significantly higher serum concentrations of glucose, glycated hemoglobin, V-CAM and PAI-1 compared to control group. Adiponectin levels tended to be lower in diabetic group, while resistin concentrations did not differ from control group. Rosiglitazone treatment improved diabetes compensation, significantly reduced VCAM-1, PAI-1 and E-selectin concentrations and increased adiponectin levels, while it did not affect serum resistin concentrations. Adiponectin concentrations at baseline were inversely related to E-selectin and MPO levels, this correlation disappeared after rosiglitazone treatment. We conclude that 5-month rosiglitazone treatment significantly reduced several markers of endothelial dysfunction. This effect could be at least in part attributable to marked increase of circulating adiponectin levels., R. Doležalová, M. M. Haluzík, L. Bošanská, Z. Lacinová, Z. Kasalová, T. Štulc, M. Haluzík., and Obsahuje bibliografii a bibliografické odkazy

Language:

English

Rights:

http://creativecommons.org/licenses/by-nc-sa/4.0/
policy:public

Source:

Physiological research | 2007 Volume:56 | Number:6

Harvested from:

CDK

Metadata only:

false